Cargando…

A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers

This single-center retrospective observational study aimed to identify risk factors for developing denosumab-related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuma, Satoe, Matsuda, Yuhei, Nariai, Yoshiki, Karino, Masaaki, Suzuki, Ritsuro, Kanno, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281320/
https://www.ncbi.nlm.nih.gov/pubmed/32408510
http://dx.doi.org/10.3390/cancers12051209
_version_ 1783543895872765952
author Okuma, Satoe
Matsuda, Yuhei
Nariai, Yoshiki
Karino, Masaaki
Suzuki, Ritsuro
Kanno, Takahiro
author_facet Okuma, Satoe
Matsuda, Yuhei
Nariai, Yoshiki
Karino, Masaaki
Suzuki, Ritsuro
Kanno, Takahiro
author_sort Okuma, Satoe
collection PubMed
description This single-center retrospective observational study aimed to identify risk factors for developing denosumab-related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least twice between July 2014 and October 2018 were included. We surveyed their demographics, medical history, blood test, underlying disease, and intraoral findings. Fourteen patients (11.4%) developed DRONJ within a mean denosumab administration period of 4 months (range: 2–52 months). Univariate analyses showed a statistically significant correlation between DRONJ and hormone therapy, chemotherapy/molecular target drug, apical periodontitis, periodontal disease, sex and body mass index. Multivariate analysis showed a statistically significant correlation between DRONJ and hormone therapy (odds ratio [OR], 22.07; 95% confidence interval [CI], 2.86–170.24), chemotherapy and/or molecular targeted therapy (OR, 18.61; 95% CI, 2.54–136.27), and apical periodontitis (OR, 22.75; 95% CI, 3.20–161.73). These findings imply that collaborative oral examinations by oral specialists may reduce the risk of development of DRONJ in patients treated with denosumab for bone metastases from solid cancers.
format Online
Article
Text
id pubmed-7281320
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72813202020-06-19 A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers Okuma, Satoe Matsuda, Yuhei Nariai, Yoshiki Karino, Masaaki Suzuki, Ritsuro Kanno, Takahiro Cancers (Basel) Article This single-center retrospective observational study aimed to identify risk factors for developing denosumab-related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least twice between July 2014 and October 2018 were included. We surveyed their demographics, medical history, blood test, underlying disease, and intraoral findings. Fourteen patients (11.4%) developed DRONJ within a mean denosumab administration period of 4 months (range: 2–52 months). Univariate analyses showed a statistically significant correlation between DRONJ and hormone therapy, chemotherapy/molecular target drug, apical periodontitis, periodontal disease, sex and body mass index. Multivariate analysis showed a statistically significant correlation between DRONJ and hormone therapy (odds ratio [OR], 22.07; 95% confidence interval [CI], 2.86–170.24), chemotherapy and/or molecular targeted therapy (OR, 18.61; 95% CI, 2.54–136.27), and apical periodontitis (OR, 22.75; 95% CI, 3.20–161.73). These findings imply that collaborative oral examinations by oral specialists may reduce the risk of development of DRONJ in patients treated with denosumab for bone metastases from solid cancers. MDPI 2020-05-12 /pmc/articles/PMC7281320/ /pubmed/32408510 http://dx.doi.org/10.3390/cancers12051209 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Okuma, Satoe
Matsuda, Yuhei
Nariai, Yoshiki
Karino, Masaaki
Suzuki, Ritsuro
Kanno, Takahiro
A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
title A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
title_full A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
title_fullStr A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
title_full_unstemmed A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
title_short A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
title_sort retrospective observational study of risk factors for denosumab-related osteonecrosis of the jaw in patients with bone metastases from solid cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281320/
https://www.ncbi.nlm.nih.gov/pubmed/32408510
http://dx.doi.org/10.3390/cancers12051209
work_keys_str_mv AT okumasatoe aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT matsudayuhei aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT nariaiyoshiki aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT karinomasaaki aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT suzukiritsuro aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT kannotakahiro aretrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT okumasatoe retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT matsudayuhei retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT nariaiyoshiki retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT karinomasaaki retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT suzukiritsuro retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers
AT kannotakahiro retrospectiveobservationalstudyofriskfactorsfordenosumabrelatedosteonecrosisofthejawinpatientswithbonemetastasesfromsolidcancers